课题基金 / 基金详情

A novel target for type 1 diabetes

A novel target for type 1 diabetes
1 型糖尿病的新靶点
批准号:
8012354
负责人:
Deyu Fang
金额:
$9.77万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2010-05-31

项目摘要

项目成果

Deyu Fang的其他基金

相关文献

中文摘要
翻译
1型糖尿病(T1D)是一种自身免疫性疾病,由胰岛素分泌的永久性破坏引起 胰腺中的β细胞通过自我攻击免疫细胞。这些自我攻击的免疫T细胞 一般在开发阶段就被淘汰,如果发生任何泄漏,应该在外围容忍。 因此,T细胞耐受性的诱导/维持失败对T1D至关重要。然而,分子 诱导/维持T细胞耐受的机制在很大程度上仍不清楚。在这里我们找到了 Sirt1功能的丧失会导致免疫反应异常升高和外周血细胞崩溃 T细胞的耐受性。结果,Sirt1-/-小鼠产生了自发的自身免疫。那些结果 提示Sirt1是T细胞激活的负性调节因子,是维持T细胞耐受所必需的。它是 因此,没有Sirt1的小鼠可能会患上T1D。Sirt1被小分子激活,如 白藜芦醇可以通过抑制攻击β细胞的自身免疫T细胞来潜在地用于治疗T1D。的确, 我们实验室的一项初步研究结果表明,Sirt1的激活剂白藜芦醇对NOD小鼠具有保护作用 来自T1D。 因此,这项提议旨在确定Sirt1如何发挥作用的分子机制。 T细胞无能因子,并研究Sirt1功能失调如何参与糖尿病的发生发展。 T1D。我们还将进一步确定白藜芦醇对T1D的预防/治疗作用。 我们提出的研究结果可能揭示T细胞耐受的一种新的分子机制。 这项研究还将确定治疗T1D的潜在治疗试剂。
英文摘要
The type 1 diabetes (T1D) is an autoimmune disease that is caused by the permanent destruction of insulinproducing beta cells in pancreas by self-attacking immune cells. These self-attacking immune T cells are generally eliminated during development stage, and should be tolerized in the periphery if any leaking occurs. Therefore, a failure in the induction/maintenance of T-cell tolerance is crucial for T1D. However, the molecular mechanisms by which T-cell tolerance is induced/maintained remain largely unknown. Here we have found that loss of Sirt1 functions causes abnormally elevated immune responses and a break-down of peripheral tolerance of T cells. As a consequence, Sirt1-/- mice develop spontaneous autoimmunity. Those results indicate that Sirt1 is a negative regulator of T-cell activation and is required to maintain T-cell tolerance. It is therefore possible that mice without Sirt1 may develop T1D. Activation of Sirt1 by small molecules like resveratrol can potentially be used to treat T1D by inhibiting beta-cell-attacking autoimmune T cells. Indeed, results from a pilot study in our laboratory indicate that the activator of Sirt1, resveratrol, protected NOD mice from T1D. Therefore, this proposal aims to determine the molecular mechanisms underlying how Sirt1 functions an anergic factor of T-cells, and to investigate how dysregulated Sirt1 functions are involved in the development of T1D. We will also further determine the preventive/treating effects of resveratrol on T1D. Results from our proposed research are likely to uncover a novel molecular mechanism of T-cell tolerance. This study will also indentify potential therapeutic reagents for T1D.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
VPS72 controls Treg cell stability and adaptation to tumor microenvironment
Clinical analysis and therapeutic development of exosomal ACE2
Clinical analysis and therapeutic development of exosomal ACE2
A deubiquitination module controls Treg adaptation to tumor microenvironment